November 28, 2022

Escient Pharmaceuticals Announces $120 Million Series C Financing

Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and EP547 to multiple clinical milestones SAN DIEGO, Calif., November 28, 2022 – Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the […]

Read More
November 17, 2022

Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus

SAN DIEGO, Calif., November 17, 2022 – Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the initiation of a Phase 2 clinical study of EP547 in subjects with cholestatic pruritus. EP547 is a highly selective antagonist of MRGPRX4, a cell […]

Read More
November 16, 2022

Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires

SAN DIEGO, Calif., November 16, 2022 – Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team. Aaron Mishel has joined the company as Chief Financial Officer, David Houck as Vice […]

Read More
January 5, 2022

Escient Pharmaceuticals Appoints Joshua Grass as CEO

– Alain Baron, M.D., Escient Co-founder and CEO Retires – SAN DIEGO, Calif., January 5, 2022 — Escient Pharmaceuticals, a clinical-stage company focused on discovering and developing novel, first-in-class therapies to address serious, unserved medical needs, today announced the appointment of Joshua Grass as Chief Executive Officer effective immediately. Mr. Grass will join the company’s Board of Directors. He […]

Read More
November 4, 2021

Escient Pharmaceuticals Announces Data Presentations Highlighting the Preclinical and Clinical Development of EP547 at AASLD The Liver Meeting® Digital Experience 2021

– EP547, a potent, highly selective MrgprX4 antagonist, represents a novel, targeted approach to the treatment of cholestatic and uremic pruritus – SAN DIEGO, Calif., November 4, 2021 — Escient Pharmaceuticals, a clinical-stage, Mas-Related G Protein-Coupled Receptor (Mrgpr)-based platform company focused on discovering and developing novel MOA-targeted, first-in-class, oral, once-daily therapies to address serious, unserved medical needs, […]

Read More
July 14, 2021

Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP547, an MrgprX4-Targeted Oral Therapy for Cholestatic and Uremic Pruritus

– EP547 was safe, well-tolerated at all doses tested and demonstrated a dose-linear PK profile supportive of oral, once-daily dosing – SAN DIEGO, CA, July 14, 2021 — Escient Pharmaceuticals, a clinical-stage, Mas-Related G Protein-Coupled Receptor (Mrgpr)-based platform company focused on discovering and developing novel MOA-targeted, first-in-class, oral, once-daily therapies to address serious, unserved medical needs, today […]

Read More
May 17, 2021

Escient Pharmaceuticals Appoints Christian Weyer, M.D., M.A.S., as President and Chief Medical Officer

SAN DIEGO, CA, May 17, 2021 — Escient Pharmaceuticals, Inc., a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced that Christian Weyer, M.D., M.A.S., has joined the company as President and Chief Medical Officer. “Christian is a proven business […]

Read More
May 3, 2021

Escient Pharmaceuticals Names Svetlana Makhni as Chief Financial Officer

SAN DIEGO, CA, May 3, 2021 — Escient Pharmaceuticals, Inc., a clinical-stage, industry-leading platform company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications, today announced the appointment of Svetlana Makhni as Chief Financial Officer effective May 3, 2021. Ms. Makhni will oversee Escient’s finance, accounting, […]

Read More
September 23, 2020

Escient Pharmaceuticals Appoints Veena Viswanath, Ph.D., as VP of Translational Biology and Drug Discovery

SAN DIEGO, CA; September 23, 2020 — Escient Pharmaceuticals, Inc., an industry-leading, clinical-stage company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, underserved medical needs across a broad range of therapeutic indications, today announced the hiring of Veena Viswanath as Vice President of Translational Biology and Drug Discovery. Prior to this new role, […]

Read More
September 14, 2020

Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritus

— Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases — Financing round led by Sanofi Ventures and Cowen Healthcare Investments and included new investors Redmile Group and Perceptive Advisors — Jason Hafler, Ph.D., of Sanofi Ventures and Kevin Raidy of Cowen Healthcare Investments join […]

Read More
September 24, 2019

Escient Pharmaceuticals Announces Appointment of K. Peter Hirth to Board of Directors

—Co-founder, former CEO of Plexxikon brings proven track record building platform-based companies and delivering novel medicines for patients— SAN DIEGO, CA; September 24, 2019—Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, today announced the appointment of K. Peter Hirth […]

Read More
July 17, 2019

Escient Pharmaceuticals Appoints Kristin Taylor, PhD as Vice President and Head of Clinical Development

— Seasoned industry leader to steer Escient’s clinical development and regulatory strategies as it advances first-in-class Mrgpr-focused pipeline — SAN DIEGO, CA; July 17, 2019—Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, announced today that Kristin Taylor, PhD has […]

Read More
October 10, 2018

Kathleen Sereda Glaub Appointed Independent Director of Escient Pharmaceuticals

–Industry veteran brings extensive corporate development, financing and
company-building expertise as Escient advances first-in-class GPCR-targeted drugs–

SAN DIEGO, CA; October 10, 2018 — Escient Pharmaceuticals, Inc., a biotechnology company advancing first-in-class G Protein Coupled Receptor (GPCR)-targeted drugs to address unmet needs for a broad range of therapeutic indications, announced today that Kathleen Sereda Glaub has been appointed to its board as an independent director.

Read More
May 9, 2018

Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs

SAN DIEGO–(BUSINESS WIRE)–Escient Pharmaceuticals launched today with the completion of a $40 million Series A financing to advance first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs), Escient will initially pursue therapies for neuro-immuno-inflammatory and autoreactive diseases. The company will use proceeds from the Series A financing, syndicated by The Column Group and 5AM Ventures and joined by Osage University Partners, to build out its team, advance its pipeline, and progress its initial preclinical programs to clinical study.

Read More